Status:
COMPLETED
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetes Mellitus, Type 2
Hypertension
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
The primary objective is to evaluate the effect of 9 weeks treatment with either telmisartan or ramipril on NO bioavailability in the renal vasculature, measured as renal plasma flow (RPF) in response...
Detailed Description
This study was designed as a randomised, double-blind, double-dummy, parallel group in hypertensive patients with type 2 diabetes and normo- or microalbuminuria over a treatment period of 9 weeks. Af...
Eligibility Criteria
Inclusion
- Hypertensive patients aged 30-80 years with type 2 diabetes, normo- or microalbuminuria, GFR \> 80 mL/min (Cockroft-Gault)
Exclusion
- None
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2004
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00240422
Start Date
February 1 2003
End Date
July 1 2004
Last Update
November 8 2013
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Lyon, France
2
Boehringer Ingelheim Investigational Site
Montpellier, France
3
Friedrich-Alexander-Universität
Erlangen, Germany, 91054
4
Boehringer Ingelheim Investigational Site
Nuremberg, Germany, 90402